We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Polar Capital Healthcare Opportunities Class I - Income (USD)

Sell:$83.21 Buy:$83.21 Change: $0.60 (0.72%)
Prices as at 19 March 2026
Sell:$83.21
Buy:$83.21
Change: $0.60 (0.72%)
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Prices as at 19 March 2026
Sell:$83.21
Buy:$83.21
Change: $0.60 (0.72%)
Prices as at 19 March 2026
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Asset Allocation

X-ray asset allocation
Key % Net Assets
International Equities 98.99%
Cash and Equiv. 0.91%
Mutual Funds 0.10%

Top 10 holdings

Stock name % Weight Country Sector
1 ELI LILLY AND COMPANY 9.26% USA Pharmaceuticals & Biotechnology
2 ARGENX SE 6.38% NLD Pharmaceuticals & Biotechnology
3 TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5.90% ISR Pharmaceuticals & Biotechnology
4 ROCHE HOLDING AG 5.68% CHE Pharmaceuticals & Biotechnology
5 CHUGAI PHARMACEUTICAL CO 5.24% JPN Pharmaceuticals & Biotechnology
6 NOVO NORDISK A/S 4.60% DNK Pharmaceuticals & Biotechnology
7 FRESENIUS SE & CO. KGAA 4.46% DEU Health Care Providers
8 TORRENT PHARMACEUTICALS LTD 4.14% IND Pharmaceuticals & Biotechnology
9 ZEALAND PHARMA A/S 3.90% DNK Pharmaceuticals & Biotechnology
10 ENLIVEN THERAPEUTICS INC 3.32% USA Pharmaceuticals & Biotechnology

Fund Analysis is only available on the desktop version of our website. This can be accessed using a desktop or laptop PC or some larger tablets.

You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account